Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: We previously reported that high body weight was a risk factor affecting the onset of anti-epidermal growth factor receptor (EGFR) antibody drug-induced acneiform rash. The current study investigated the relationship between risk factors for anti-EGFR antibody drug-induced acneiform rash and survival probability in colorectal cancer patients, as well as effects of drug withdrawal, dose reduction, or treatment discontinuation on treatment continuation.
Methods: This retrospective study included 67 patients with unresectable advanced or recurrent colorectal cancer treated with anti-EGFR antibody drugs for the first time.
Results: The survival time and acneiform rash grade of patients with high body weight (≥ 67.2 kg) were significantly longer and higher than those of patients with low body weight (< 67.2 kg). Moreover, the treatment continuation time of patients with drug withdrawal or dose reduction was significantly longer than that of patients without drug withdrawal or dose reduction or with/without treatment discontinuation. Meanwhile, the treatment continuation time of patients with treatment discontinuation was significantly shorter than that of patients with drug withdrawal or dose reduction or those without drug withdrawal, dose reduction, or treatment discontinuation.
Conclusions: High body weight is a novel prognostic factor for patients receiving cancer drugs with anti-EGFR antibody drugs. Hence, the results of this study suggest that patients with high body weight should be carefully monitored for the development of acneiform rash when receiving anti-EGFR antibody drugs as cancer drug therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434966 | PMC |
| http://dx.doi.org/10.1186/s40780-022-00253-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team.
Int J Clin Oncol
September 2025
Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1Minato-Ku, Shirokanedai, Tokyo, 108-8639, Japan.
Epidermal growth factor receptor antibodies and tyrosine kinase inhibitors cause various skin toxicities. Acneiform rash, paronychia, and pruritus are the major side effects, and their incidence is high, especially in Asian patients. These skin disorders greatly reduce the patients' quality of life and can affect treatment intensity.
View Article and Find Full Text PDFExosome-Based Therapy for Skin Complications in Oncology Patients Treated with EGFR Inhibitors: A Case Report Highlighting the Need for Coordinated Dermato-Oncologic Care.
Pharmaceuticals (Basel)
July 2025
Stem Cell Laboratory, Małopolskie Centrum Biotechnologii UJ, ul. Gronostajowa 7A, 30-387 Kraków, Poland.
Patients undergoing epidermal growth factor receptor inhibitor (EGFRI) therapy frequently experience dermatologic side effects, notably papulopustular rash, which impacts 50-90% of recipients. This rash typically appears on the face, chest, and back within weeks of treatment, resembling acne but stemming from distinct pathophysiological mechanisms, causing significant discomfort and reduced quality of life. Prophylactic measures and symptom-based treatment are recommended, emphasizing patient education, topical agents, and systemic therapies for severe cases.
View Article and Find Full Text PDFTrametinib in Adults with Neurofibromatosis Type 1-Related Symptomatic Plexiform Neurofibromas.
Ann Neurol
August 2025
Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Objective: Mitogen-activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
Methods: Thirty patients with a diagnosis of generalized or mosaic neurofibromatosis type 1 and a symptomatic inoperable plexiform neurofibroma were treated with 2mg trametinib per day.
Safety Evaluation of SH003 and Docetaxel Combination in Patients With Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial.
Integr Cancer Ther
August 2025
Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Kyungheedae-ro, Dongdaemun-gu, Seoul, Korea.
Background: Cancer remains one of the leading causes of death worldwide, underscoring the need for novel therapies. SH003, an herbal mixture composed of , , and , is a traditional Korean medicine formulation with potential to enhance chemotherapy efficacy and reduce toxicity. This study aimed to assess the safety and determine maximum tolerated dose of SH003 in combination with docetaxel in patients with advanced solid tumors, specifically lung and breast cancer.
View Article and Find Full Text PDFPhase I clinical trial of the bifunctional EGFR/TGF-β fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors.
Clin Cancer Res
July 2025
Dana-Farber Cancer Institute, Boston, MA, United States.
Purpose: To evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of ficerafusp alfa (BCA101), a first-in-class bifunctional protein targeting epidermal growth factor receptor (EGFR) and TGF-β, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
Patients And Methods: At escalating doses in a parallel 3+3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa monotherapy (64-1500 mg) or in combination (240-1500 mg) with pembrolizumab (200 mg intravenously every 3 weeks). The primary objective was to determine safety/tolerability.